Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-190X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry ; volume:34 ; number:1 ; day:16 ; month:11 ; year:2019 ; pages:89-98 ; date:2.2020
BioDrugs ; 34, Heft 1 (16.11.2019), 89-98, 2.2020
- Creator
-
Kim, Hyoun-Ah
Lee, Eunyoung
Lee, Sun-Kyung
Park, Yong-Beom
Lee, Young Nam
Kang, Hee Jung
Shin, Kichul
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40259-019-00393-y
- URN
-
urn:nbn:de:101:1-2020042622491901572411
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kim, Hyoun-Ah
- Lee, Eunyoung
- Lee, Sun-Kyung
- Park, Yong-Beom
- Lee, Young Nam
- Kang, Hee Jung
- Shin, Kichul
- SpringerLink (Online service)
Other Objects (12)
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score–Matched Analysis from the Korean College of Rheumatology Biologics Registry
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
What is the future of targeted therapy in rheumatology: biologics or small molecules?
Real-world retention rates of biologics in patients with rheumatoid arthritis
Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Rheumatology
The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries
Imaging in rheumatology: reconciling radiology and rheumatology
Biologics in therapy
BMC Rheumatology
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score–Matched Analysis from the Korean College of Rheumatology Biologics Registry
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
What is the future of targeted therapy in rheumatology: biologics or small molecules?
Real-world retention rates of biologics in patients with rheumatoid arthritis
Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Rheumatology
The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries
Imaging in rheumatology: reconciling radiology and rheumatology
Biologics in therapy
BMC Rheumatology
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score–Matched Analysis from the Korean College of Rheumatology Biologics Registry
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
What is the future of targeted therapy in rheumatology: biologics or small molecules?
Real-world retention rates of biologics in patients with rheumatoid arthritis
Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Rheumatology
The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries
Imaging in rheumatology: reconciling radiology and rheumatology
Biologics in therapy